SPEECH-PROCESSING-SOLU
21.6.2016 09:03:13 CEST | Business Wire | Press release
Speech Processing Solutions , the international leader in professional dictation, just launched a new dictation microphone. The improved SpeechMike Premium Touch comes with an innovative touch sensor for optimized and ergonomic navigation, including reduced thumb movement, and an enhanced barcode scanner for quick and easy file association. In addition to these user-friendly updates, the device can scan even more types of bar- and QR codes than its predecessor. The SpeechMike Premium Touch dictation microphone lets healthcare, legal and business professionals dictate their documents, saving them time and resources by allowing them to accomplish their core tasks – benefits that can be directly passed on to their clients.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160621005179/en/
Renowned for its superior microphone quality
The Philips SpeechMike Premium has long been known for its crystal-clear recording quality, and sets the standard for dictation devices worldwide. The free-floating microphone guarantees that almost no background, touch, click, air or structure-borne noise is recorded. “The SpeechMike Premium has established itself as THE benchmark for professional dictation microphones in the industry,” said Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Unrivaled recording quality and noise canceling capabilities, as well as its perfect ergonomics and the antimicrobial surface make it a perfect tool for professional dictation users. These functions are especially helpful for attorneys and medical personnel.”
Focus on content
The new device is equipped with a durable touch sensor. Users can accurately control their mouse cursor using the new SpeechMike Premium Touch. This allows them to easily use and navigate within applications while recording, without having to switch between the mouse and microphone .
Less frequently used functions are placed above or below the sensor, and clearly delineated. Clearly marked distances and different shapes are perfect for operating the device without constantly looking down. Even the Premium Touch’s flip side is optimized for ergonomic and easy use: “Trigger” and “Command” buttons are placed just right to prevent unwanted activation. The key is to focus on content rather than complicated usage instructions. Configurable functions permit a personalized workflow, and an integrated movement sensor that mutes the microphone when not in use adds a finishing touch. “The new features guarantee smooth and convenient operation, even when recording over longer periods of time every day. The Premium Touch can also read more barcodes than its predecessor, allowing end users to quickly categorize and associate client and patient data. The results are enhanced security and potential cost savings,” said Brauner.
Speech to text made easy
Philips SpeechMike Premium Touch makes going from recording your voice to a written document a simple process. The dictation microphone is easy to integrate into users’ IT infrastructures, and works in harmony with existing software, both in large hospitals or small businesses. Thanks to the excellent recording quality, Philips SpeechMike Premium Touch is perfectly suited for transcription, whether by an assistant, speech recognition software, or Philips dictation workflow solutions such as SpeechLive and SpeechExec.
Philips SpeechLive dictation solution
Philips workflow software creates a smooth and safe work cycle between authors and transcriptionists. “Philips SpeechLive is a perfect solution for people like myself, who are on the go a lot. It guarantees a reliable and safe transmission of dictations, regardless of what time it is” explained Dr. Peter Klein, partner at the international law firm PFKA, in Austria adding that: “The offered transcription service is another advantage, particularly in foreign languages such as French, as it virtually increases our office’s capacity.”
For more information on the Philips SpeechMike Premium Touch (SMP3700/3800 series) visit: www.philips.com/dictation
Philips is now offering a free 30-day SpeechLive trial including 10 free transcription minutes at: www.speechlive.com
About Speech Processing Solutions
Speech Processing Solutions is the global number one in professional dictation. Founded in Austria in 1954 as part of Philips, the company has been the driving force in speech-to-text innovations for over 60 years. Always striving for excellence and putting emphasis on outstanding quality, the company has designed groundbreaking products, such as the portable Philips Pocket Memo voice recorder , the Philips SpeechMike Premium dictation microphone and the Philips SpeechExec dictation recorder app for smartphones. The latest innovation, Philips SpeechLive , makes dictation quicker and more convenient than ever before, by bringing secure dictation workflow to the cloud and enabling seamless speech-to-text with the new speech recognition service. With solutions perfectly tailored to individual industry needs, Speech Processing Solutions has helped millions of satisfied customers around the globe save time and resources, allowing them to work as efficiently as possible.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20160621005179/en/
Contact:
Speech Processing Solutions
Lea Pachta
lea.pachta@speech.com
Tel:
+43 1 60529-1744
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom